Singapore – The PDA Pharma Manufacturing & Quality Conference 2025 brought together the brightest minds in APAC’s pharmaceutical industry, and Siddhi Sai International (SSI) was honored to participate. As we reflect on this transformative event, we’re energized by the collaborations, insights, and shared commitment to elevating sterile manufacturing quality across the region.
Key Takeaways from the Conference
- Evolving Regulatory Priorities
- Robust discussions on EMA Annex 1 and USP <1790> updates, emphasizing stricter visible particulate control.
- Growing demand for standardized defect libraries to bridge manual and AVI inspection gaps.
- Industry Challenges
- Lyophilized product inspection emerged as a top pain point, with SSI’s color-matched kits garnering attention.
- Audit readiness remains critical, with 60% of attendees prioritizing QC documentation.
- SSI’s Contribution
- Showcased our next-gen Visual Inspection Qualification Kits, featuring:
- 3-year shelf life technology for particle stability.
- NIST-traceable defects for audit-proof compliance.
- Demonstrated floating particle solutions to prevent adhesion in pre-filled syringes.
- Showcased our next-gen Visual Inspection Qualification Kits, featuring:
Why Our Solutions Resonated
🔬 For QA Teams:
- “Your POD kits simplified our USP <1790> requalification process.” – QC Head, Biologics Firm
🤝 For Industry Partners:
- “SSI’s customized BFS kits solved our leak-test validation hurdles.” – CDMO Representative
Gratitude & Next Steps
A heartfelt thank you to:
- PDA APAC for curating this knowledge-sharing platform.
- Attendees who explored our booth and shared their inspection challenges.
- Peers who inspired us with innovations in automation and AI-driven QC.